Admissions Open
Admissions Open
Current Pharmaceutical Biotechnology has been an extremely important Journal of Bentham Science Publishers. The current issue has been focused on to understanding the complex molecular links and pathways establishing a harmony between iron chelation and drug resistance either in cancer or tuberculosis. The contributions from diverse range of authors reflect the need to re-evaluate current therapeutic regimens and to revolutionize the approaches for improved therapy. The current issue is surely going to enhance and strengthen the understanding of multidisciplinary experts from academia, research. Rai et al. shed light on host-Mycobacterium tuberculosis interaction and its effectiveness in containment of tuberculosis. Authors further emphasized upon the physiological balance of iron, its pathogen driven possible perturbance and finally effect of these parameters on the outcome of the disease. Authors speculate for laying down an approach to inhibit the iron acquisition in M. tuberculosis bacilli by targeting mycobactin which will inhibit the growth of the bacilli and further containment of the disease [1]. Chatterjee et al. stressed upon delineating the mechanism pertaining to various types of cancers that render them resistant against therapeutic drugs. Multiple features like the biological characteristics, target points and signaling cascade mediators of cancer pathways have been elucidated paving the way for suitable therapies for the treatment of Multi Drug Resistance [2-4]. Zghair et al. emphasized upon an intricate link between estrogen and iron metabolism having a great prognostic value in predicting clinical outcome in hormone responsive breast cancer patients [5]. The review highlights some of the major advances in the area of iron chelation therapy and more precisely the role of iron in hormone receptor positive breast cancer envisaging new mechanistic insights into breast cancer therapeutics.